Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01698645|
Recruitment Status : Unknown
Verified July 2013 by Archimedes Development Ltd.
Recruitment status was: Recruiting
First Posted : October 3, 2012
Last Update Posted : July 11, 2013
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
|Condition or disease||Intervention/treatment|
|Breakthrough Cancer Pain||Drug: PecFent® (fentanyl) nasal spray|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||December 2014|
Drug: PecFent® (fentanyl) nasal spray
- Satisfaction [ Time Frame: Satisfaction will be assessed approximately 1 hour after each breakthrough pain (BTPc) episode treated with PecFent® from completion of titration through Day 7 ]Satisfaction will be assessed using a 4-point Likert scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01698645
|Contact: Yolanda Riesgo, MD||+ 34 firstname.lastname@example.org|
|Hospital 12 de Octubre||Recruiting|
|Madrid, Spain, 28041|
|Contact: Hernan Cortes, MD + 34 913 908 349 email@example.com|
|Principal Investigator: Hernan Cortes, MD|